公开(公告)号：EP1827492B1

公开(公告)日：2010-08-11

申请号：EP05852645.0

申请日：2005-11-30

申请人： Curagen Corporation ,  Abgenix, Inc.

发明人： RASTELLI, Luca ,  POLLACK, Vincent, A. ,  TSE, Kam, Fai ,  KLAKAMP, Scott ,  FOORD, Orit ,  LIANG, Meina ,  JIA, Xiao-Chi ,  XIAO, Feng ,  LICHENSTEN, Henri ,  HERRMANN, John ,  LAROCHELLE, William, J. ,  JEFFERS, Michael, E. ,  CHAPOVAL, Andrei ,  MEZES, Peter ,  ARA, Gulshan ,  TORGOV, Michael ,  KARKARIA, Cyrus ,  DAVAGNINO, Juan

IPC分类号： A61K39/395 ,  A61K47/48 ,  A61P35/00 ,  C07K16/30 ,  C07K19/00 ,  C12N1/21 ,  C12N15/13 ,  C12N15/63 ,  C12N5/10 ,  G01N33/574 ,  G01N33/577

CPC分类号： C07K16/3053 ,  A61K47/6803 ,  A61K47/6849 ,  A61K47/6851 ,  A61K2039/505 ,  A61K2039/545 ,  C07K16/2809 ,  C07K16/30 ,  C07K16/3061 ,  C07K2317/21 ,  C07K2317/31 ,  C07K2317/565 ,  C07K2317/62 ,  C07K2317/622 ,  C07K2317/73 ,  C07K2317/732 ,  C07K2317/77 ,  C07K2317/94

摘要： The present invention provides fully human lonoclonal antibodies that specifically bind to GPNMB, and uses thereof. Nucleotide sequences encoding, and amino acid sequences comprising, heavy and light chain immunoglobulin molecules, particularly sequences corresponding to contiguous heavy and light chain sequences spanning the framework regions and/or complementarity determining regions (CDRs) are provided. The present invention also provides immunoconjugates comprising anti-GPNMB antibodies and methods of using such immunoconjugates. the present invention futher provides bispecific antibodies comprising an anti-GPNMB antibody component and an anti-CD3 component, and methods of using such bispecific antibodies.

公开(公告)号：EP1554576A2

公开(公告)日：2005-07-20

申请号：EP02792319.2

申请日：2002-12-02

申请人： Abgenix, Inc.

发明人： BABCOOK, John ,  KANG, Jaspal, Singh ,  JIA, Xiao-Chi ,  ZHANG, Li

IPC分类号： G01N33/53 ,  G01N33/537 ,  G01N33/566 ,  G01N33/557

CPC分类号： G01N33/6854 ,  G01N33/6857

摘要： Methods are disclosed for determining the relative binding affinities of molecules for their binding partner. One type of molecule is an antibody, which has an antigen binding partner. Antibodies are tested for binding against limited dilutions of antigen. Antibodies that bind to the most dilute antigen concentrations are determined to have a higher relative binding affinity for the antigen than antibodies that only bind to more concentrated antigen preparations.

公开(公告)号：EP1639092A2

公开(公告)日：2006-03-29

申请号：EP04777147.2

申请日：2004-06-25

申请人： Abgenix, Inc.

发明人： WEBER, Richard ,  FENG, Xiao ,  FOORD, Orit ,  GREEN, Larry ,  GUDAS, Jean ,  KEYT, Bruce ,  LIU, Ying ,  RATHANASWAMI, Palani ,  RAYA, Robert ,  YANG, Xiao, Dong ,  CORVALAN, Jose ,  FOLTZ, Ian ,  JIA, Xiao-Chi ,  KANG, Jaspal ,  KING, Chadwick, T. ,  KLAKAMP, Scott, L. ,  SU, Qiaojuan, Jane

IPC分类号： C12N1/00

CPC分类号： C07K16/30 ,  A61K47/6803 ,  A61K47/6849 ,  A61K47/6897 ,  A61K2039/505 ,  B82Y5/00 ,  C07K16/2863 ,  C07K2317/21 ,  C07K2317/34 ,  C07K2317/77 ,  C07K2317/92 ,  Y10S435/81

摘要： The present invention relates to novel antibodies, particularly antibodies directed against deletion mutants of epidermal growth factor receptor and particularly to the type III deletion mutant, EGFRvIII. The invention also relates to human monoclonal antibodies directed against deletion mutants of epidermal growth factor receptor and particularly to EGFRvIII. Diagnostic and therapeutic formulations of such antibodies, and immunoconjugates thereof, are also provided.

公开(公告)号：EP1554576B1

公开(公告)日：2007-10-03

申请号：EP02792319.2

申请日：2002-12-02

申请人： Abgenix, Inc.

发明人： BABCOOK, John ,  KANG, Jaspal, Singh ,  JIA, Xiao-Chi ,  ZHANG, Li

IPC分类号： G01N33/53 ,  G01N33/537 ,  G01N33/566 ,  G01N33/557

CPC分类号： G01N33/6854 ,  G01N33/6857

摘要： Methods are disclosed for determining the relative binding affinities of molecules for their binding partner. One type of molecule is an antibody, which has an antigen binding partner. Antibodies are tested for binding against limited dilutions of antigen. Antibodies that bind to the most dilute antigen concentrations are determined to have a higher relative binding affinity for the antigen than antibodies that only bind to more concentrated antigen preparations.

公开(公告)号：EP1578947A2

公开(公告)日：2005-09-28

申请号：EP03796557.1

申请日：2003-12-02

申请人： Abgenix, Inc. ,  Lexicon Genetics Incorporated

发明人： LANDES, Gregory, M. ,  HAAK-FRENDSCHO, Mary ,  CHEN, Ling ,  LEE, Yen-Wah, Rozanne ,  LIANG, Meina, L. ,  FENG, Xiao ,  JIA, Xiao-Chi ,  NOCERINI, Mark, R.

IPC分类号： C12N1/00

CPC分类号： C07K16/40 ,  A61K2039/505 ,  C07K2317/21 ,  C07K2317/565

摘要： The invention described herein relates to antibodies directed to the antigen phospholipase A2 (PLA2) and uses of such antibodies. In particular, in accordance with some embodiments of the invention, there are provided fully human monoclonal antibodies directed to the antigen PLA2. Nucleotide sequences encoding, and amino acid sequences comprising, heavy and light chain immunoglobulin molecules, particularly sequences corresponding to contiguous heavy and light chain sequences spanning the framework regions and/or complementarity determining regions (CDRs), specifically from FR1 through FR4 or CDR1 through CDR3, are provided. Hybridomas or other cell lines expressing such immunoglobulin molecules and monoclonal antibodies are also provided.

公开(公告)号：EP1476185A2

公开(公告)日：2004-11-17

申请号：EP02802898.3

申请日：2002-11-08

申请人： Pfizer Products Inc. ,  Abgenix, Inc.

发明人： BEDIAN, Vahe ,  GLADUE, Ronald, P. ,  CORVALAN, Jose ,  JIA, Xiao-Chi ,  FENG, Xiao

IPC分类号： A61K39/395 ,  C07K16/28 ,  C12N5/10 ,  C12N15/00 ,  C12N15/11 ,  C12N15/12 ,  C12N15/63

CPC分类号： C07K16/2866 ,  A01K2217/05 ,  A61K39/3955 ,  A61K45/06 ,  A61K48/00 ,  A61K2039/505 ,  A61N5/062 ,  A61N5/10 ,  C07K16/2878 ,  C07K16/40 ,  C07K2317/14 ,  C07K2317/21 ,  C07K2317/33 ,  C07K2317/34 ,  C07K2317/56 ,  C07K2317/565 ,  C07K2317/75 ,  C07K2317/92

摘要： The present invention relates to antibodies and antigen-binding portions thereof that specifically bind to CD40, preferably human CD40, and that function as CD40 agonists. The invention also relates to human anti-CD40 antibodies and antigen-binding portions thereof. The invention also relates to antibodies that are chimeric, bispecific, derivatized, single chain antibodies or portions of fusion proteins. The invention also relates to isolated heavy and light chain immunoglobulins derived from human anti-CD40 antibodies and nucleic acid molecules encoding such immunoglobulins. The present invention also relates to methods of making human anti-CD40 antibodies, compositions comprising these antibodies and methods of using the antibodies and compositions for diagnosis and treatment. The invention also provides gene therapy methods using nucleic acid molecules encoding the heavy and/or light immunoglobulin molecules that comprise the human anti-CD40 antibodies. The invention also relates to transgenic animals comprising nucleic acid molecules of the present invention.

公开(公告)号：EP1827492A2

公开(公告)日：2007-09-05

申请号：EP05852645.0

申请日：2005-11-30

申请人： Curagen Corporation ,  Abgenix, Inc.

发明人： RASTELLI, Luca ,  POLLACK, Vincent, A. ,  TSE, Kam, Fai ,  KLAKAMP, Scott ,  FOORD, Orit ,  LIANG, Meina ,  JIA, Xiao-Chi ,  XIAO, Feng ,  LICHENSTEN, Henri ,  HERRMANN, John ,  LAROCHELLE, William, J. ,  JEFFERS, Michael, E. ,  CHAPOVAL, Andrei ,  MEZES, Peter ,  ARA, Gulshan ,  TORGOV, Michael ,  KARKARIA, Cyrus ,  DAVAGNINO, Juan

IPC分类号： A61K39/395 ,  A61K47/48 ,  A61P35/00 ,  C07K16/30 ,  C07K19/00 ,  C12N1/21 ,  C12N15/13 ,  C12N15/63 ,  C12N5/10 ,  G01N33/574 ,  G01N33/577

CPC分类号： C07K16/3053 ,  A61K47/6803 ,  A61K47/6849 ,  A61K47/6851 ,  A61K2039/505 ,  A61K2039/545 ,  C07K16/2809 ,  C07K16/30 ,  C07K16/3061 ,  C07K2317/21 ,  C07K2317/31 ,  C07K2317/565 ,  C07K2317/62 ,  C07K2317/622 ,  C07K2317/73 ,  C07K2317/732 ,  C07K2317/77 ,  C07K2317/94

摘要： The present invention provides fully human lonoclonal antibodies that specifically bind to GPNMB, and uses thereof. Nucleotide sequences encoding, and amino acid sequences comprising, heavy and light chain immunoglobulin molecules, particularly sequences corresponding to contiguous heavy and light chain sequences spanning the framework regions and/or complementarity determining regions (CDRs) are provided. The present invention also provides immunoconjugates comprising anti-GPNMB antibodies and methods of using such immunoconjugates. the present invention futher provides bispecific antibodies comprising an anti-GPNMB antibody component and an anti-CD3 component, and methods of using such bispecific antibodies.

公开(公告)号：EP1660127A1

公开(公告)日：2006-05-31

申请号：EP04780015.6

申请日：2004-08-03

申请人： Pfizer Products Inc. ,  Abgenix, Inc.

发明人： MICHAUD, Neil R. ,  KAJIJI, Shama ,  BORZILLO, Gary ,  BEDIAN, Vahe ,  COLEMAN, Kevin ,  GREEN, Larry L. ,  JIA, Xiao-Chi

IPC分类号： A61K39/395 ,  C07K16/00 ,  C07H21/04 ,  C12P21/00

CPC分类号： A61K39/39558 ,  A61K2039/505 ,  C07K16/2863 ,  C07K16/3076 ,  C07K2317/21 ,  C07K2317/73 ,  C07K2317/74 ,  C07K2317/75 ,  C07K2317/76 ,  C07K2317/92

摘要： The present invention relates to antibodies including human antibodies and antigen-binding portions thereof that specifically bind to c-Met, preferably human c-Met, and that function to inhibit c-Met. The invention also relates to human anti-c-Met antibodies and antigen-binding portions thereof. The invention also relates to antibodies that are chimeric, bispecific, derivatized, single chain antibodies or portions of fusion proteins. The invention also relates to isolated heavy and light chain immunoglobulins derived from human anti-c-Met antibodies and nucleic acid molecules encoding such immunoglobulins. The present invention also relates to methods of making human anti-c-Met antibodies, compositions comprising these antibodies and methods of using the antibodies and compositions for diagnosis and treatment. The invention also provides gene therapy methods using nucleic acid molecules encoding the heavy and/or light immunoglobulin molecules that comprise the human anti-c-Met antibodies. The invention also relates to transgenic animals or plants comprising nucleic acid molecules of the present invention.

公开(公告)号：EP1638606A2

公开(公告)日：2006-03-29

申请号：EP04777034.2

申请日：2004-06-25

申请人： Abgenix, Inc.

发明人： WEBER, Richard ,  FENG, Xiao ,  FOORD, Orit ,  GREEN, Larry ,  GUDAS, Jean ,  KEYT, Bruce ,  LIU, Ying ,  RATHANASWAMI, Palani ,  RAYA, Robert ,  YANG, Xiao, Dong ,  CORVALAN, Jose ,  FOLTZ, Ian ,  JIA, Xiao-Chi ,  KANG, Jaspal ,  KING, Chadwick, T. ,  KLAKAMP, Scott, L. ,  SU, Qiaojuan, Jane

IPC分类号： A61K39/395 ,  C07K16/28 ,  C07K17/00

CPC分类号： C07K16/30 ,  A61K47/6803 ,  A61K47/6849 ,  A61K47/6897 ,  A61K2039/505 ,  B82Y5/00 ,  C07K16/2863 ,  C07K2317/21 ,  C07K2317/34 ,  C07K2317/77 ,  C07K2317/92 ,  Y10S435/81

摘要： The present invention relates to novel antibodies, particularly antibodies directed against deletion mutants of epidermal growth factor receptor and particularly to the type III deletion mutant, EGFRvIII. The invention also relates to human monoclonal antibodies directed against deletion mutants of epidermal growth factor receptor and particularly to EGFRvIII. Diagnostic and therapeutic formulations of such antibodies, and immunoconjugates thereof, are also provided.

公开(公告)号：EP1466177A2

公开(公告)日：2004-10-13

申请号：EP02789983.0

申请日：2002-12-02

申请人： Abgenix, Inc.

发明人： WALKER, Wynn, L. ,  JIA, Xiao-Chi ,  GALLO, Michael ,  KANG, Jaspal, Singh ,  BABCOOK, John ,  DAVIS, Geoff ,  GREEN, Larry ,  JOHO, Keith

IPC分类号： G01N33/53

CPC分类号： C40B30/04 ,  G01N33/5008 ,  G01N33/5011 ,  G01N33/574 ,  G01N33/68 ,  G01N33/6845 ,  G01N2500/04

摘要： Methods to screen antibodies against an antigen, categorize them according to the epitope they recognize, and rank them according to their binding affinities, thereby providing a method to rapidly and efficiently identify antibodies having potential usefulness in therapeutic products are described. Also described are methods of evaluating antibodies to determine their potential usefulness in therapeutic products.